jonzobot - I totally agree with you. I believe that had they not spun Zenith off, the cancer program would be sitting on the shelf with all of the other compounds not moving ahead. Through Zenith, we have received much better financing terms by sheltering it from the RVX failures to a degree and moved the program ahead. As slowly as it seems, it is at least moving and not just sitting on a shelf. You are also correct in assuming that the dismal RVX price, although the result of many things, the biggest by far is trial failures.